Identification of a tumor-associated contact-dependent activity which reversibly downregulates cytolytic function of CD8+ T cells

Cancer Immunity

Volumn 1, Issue , 2001, Pages 1-14

  Levey, Daniel L ^a   Udono, Heiichiro ^b   Heike, Michael ^c   Srivastava, Pramod K ^d  

^a Antigenics Inc   (United States)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Cultured tumor cells; Cytotoxic T lymphocytes; Immunologic factors; Mice; Tumor escape

Indexed keywords

3 METHYLCHOLANTHRENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; FIBROSARCOMA; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NONHUMAN; T LYMPHOCYTE; TUMOR CELL;

EID: 3142618477     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Schreiber H 1993. Tumor Immunology. In: Paul WE, editor. Fundamental Immunology. 4th ed. New York (NY): Raven Press; 1999. p. 1237-1270.
2. Bursuker I, North RJ. Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors. Cancer Immunol Immunother 1985; 19: 215-218. (PMID: 3159472)
3. North R J and Bursuker I. T cell-mediated suppression of the concomitant antitumor immune response as an example of transplantation tolerance. Transplant Proc 1984; 16: 463-469. (PMID: 6609455)
4. Rudczynski AB, Mortensen RF. Suppressor cells in mice with murine mammary tumor virus-induced mammary tumors. I. Inhibition of mitogen-induced lymphocyte stimulation. J Natl Cancer Inst 1978; 60: 205-211. (PMID: 203703)
5. Alleva DG, Walker TM, Elgert FD. Induction of macrophage suppressor activity by fibrosarcoma-derived transforming growth factor-beta 1: contrasting effects on resting and activated macrophages. J Leukoc Biol 1995; 57: 919-928. (PMID: 7790775)
6. Alleva DG, Elgert FD. Promotion of macrophage-stimulated autoreactive T cell proliferation by interleukin-10: counteraction of macrophage suppressor activity during tumor growth. Immunobiology 1995; 192: 155-171. (PMID: 7782092)
7. Garner RE, Malick AP, Yurochko AD, Elgert KD. Shifts in macrophage (M phi) surface phenotypes during tumor growth: association of Mac-2+ and Mac-3+ M phi with immunosuppressive activity. Cell Immunol 1987; 108: 255-268. (PMID: 2957065)
8. Fujii T, Igarashi T, Kishimoto S.. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice. J Natl Cancer Inst 1987; 78: 509-517. (PMID: 2950265)
9. Watson GA, Fu YX, Lopez DM. Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms. J Leukoc Biol 1991; 49: 126-138. (PMID: 1991996)
10. Walker PR, Saas P, Dietrich PY. Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol 1998; 10: 564-572. (PMID: 9794830)
11. Srivastava PK, DeLeo AB, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA 1986; 83: 3407-3411. (PMID: 3458189)
12. Udono H, Levey DL, Srivastava PK. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci USA 1994; 91: 3077-3081. (PMID: 7909157)
13. Heike M, Blachere NE, Wolfel T, Meyer zum Buschenfelde KH, Storkel S, Srivastava PK. Membranes activate tumor- and virus-specific precursor cytotoxic T lymphocytes in vivo and stimulate tumor-specific T lymphocytes in vitro: implications for vaccination. J Immunother Emphasis Tumor Immunol. 1994; 15: 165-174. (PMID: 8032539)
14. Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol 1994; 153: 1674-1686. (PMID: 8046239)
15. Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996; 67: 333-338. (PMID: 8707405)
16. Sasaki A, Naganuma H, Satoh E, Nagasaka M, Isoe S, Nakano S, Nukui H. Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells. Neurol Med Chir (Tokyo) 1995; 35: 423-430. (PMID: 7477684)
17. Sehgal I, Baley PA, Thompson TC. Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 1996; 56: 3359-3365. (PMID: 8764134)
18. Lieubeau BL, Garrigue L, Barbieux I, Meflah K, and Gregoire M. The role of transforming growth factor beta 1 in the fibroblastic reaction associated with rat colorectal tumor development. Cancer Res 1994; 54: 6526-6532. (PMID: 7987852)
19. Fischer JR, Schindel M, Stein N, Lahm H, Gallati H, Krammer PH, Drings P. Selective suppression of cytokine secretion in patients with small-cell lung cancer. Ann Oncol 1995; 6: 921-936. (PMID: 8624296)
20. van Roozendaal CE, Klijn JG, van Ooijen B, Claassen C, Eggermont AM, Henzen-Logmans SC, Foekens JA. Transforming growth factor beta secretion from primary breast cancer fibroblasts. Mol Cell Endocrinol 1995; 111: 1-6. (PMID: 7649348)
21. Sargent ER, Gomella LG, Wade TP, Ewing MW, Kasid A, Linehan WM. Expression of mRNA for transforming growth factors-alpha and -beta and secretion of transforming growth factor-beta by renal cell carcinoma cell lines. Cancer Commun 1989; 1: 317-322. (PMID: 2488683)
22. Ullrich SE. Mechanism involved in the systemic suppression of antigen-presenting cell function by UV irradiation. Keratinocyte-derived IL-10 modulates antigen-presenting cell function of splenic adherent cells. J Immunol 1994; 152: 3410-3416. (PMID: 8144924)
23. Rohrer JW, Coggin JH, Jr. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol 1995; 155: 5719-5727. (PMID: 7499859)
24. Dinapoli MR, Calderon CL, Lopez DM. The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J Exp Med 1996; 183: 1323-1329. (PMID: 8666890)
25. Sotomayor EM, DiNapoli MR, Calderon C, Colsky A, Fu YX, Lopez DM. Decreased macrophage-mediated cytotoxicity in mammary-tumor-bearing mice is related to alteration of nitric-oxide production and/or release. Int J Cancer 1995; 60: 660-667. (PMID: 7860141)
26. Calderon C, Huang ZH, Gage DA, Sotomayor EM, Lopez DM. Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidyl serine. J Exp Med 1994; 180: 945-958. (PMID: 8064242)
27. Shimizu YS, Iwatsuki R, Herberman RB Whiteside TL. Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors. Cancer Immunol Immunother 1991; 32: 280-288. (PMID: 1847844)
28. Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997; 89: 3806-3616. (PMID: 9160688)
29. Kooi S, Zhang HZ, Patenia R, Edwards CL, Platsoucas CD, Freedman RS. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 1996; 174: 116-128. (PMID: 8954611)